Collateral Therapeutics (CLTX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Collateral Therapeutics (CLTX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Silver Knife who wrote (9)	7/1/1999 12:31:00 AM
From: Jibacoa	of 35

Silver: I guess the move on CLTX is probably related to the article in Circulation last week in relation to CHF.: SAN DIEGO, June 22 /PRNewswire/ -- Collateral Therapeutics (Nasdaq: CLTX) today announced hat a new preclinical study published in the current issue of Circulation found that the AC-6 gene may improve heart function in a preclinical animal model that closely resembles human congestive heart failure (CHF). Collateral exclusively licensed the technology used in this research from the University of California in 1997 and, following the filing of an IND, expects to begin clinical trials of CORGENIC(TM), an AC-6 gene therapy treatment for clinical CHF, early next year. Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next